IL-18 代谢重编程表达 CAR 的自然杀伤 T 细胞并增强其抗肿瘤活性
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
这些发现支持利用IL-18开发下一代细胞因子武装的CAR-NKT癌症免疫疗法。
ALL SOURCES
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
这些发现支持利用IL-18开发下一代细胞因子武装的CAR-NKT癌症免疫疗法。
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
使用针对VEGF或VEGFR2的特异性抗体阻断VEGF,可增加TME中的HEV和细胞毒性CD8(+) TIL,在临床前模型中显著提高EAT策略的治疗效果,支持进一步研究VEGF阻断以增强基于BsAb的T细胞免疫疗法的临床研究。
Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation.
CAR-T 细胞疗法在血液肿瘤中已取得显著的治疗效果,而其应用于实体恶性肿瘤仍受限于约9%的汇总客观缓解率。
Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
肉瘤是一组多样化的骨和软组织肿瘤,占儿童癌症的10%以上。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。